Nucor earnings beat by $0.08, revenue fell short of estimates
MetaVia Inc., a pharmaceutical company with a market capitalization of $12.72 million, disclosed on Friday that it has received a notification of non-compliance from Nasdaq. The notice, dated May 29, 2025, informed the company that its common stock had not met the minimum bid price requirement for continued listing on The Nasdaq Capital Market for the previous 30 consecutive business days. According to InvestingPro data, the stock has fallen 83.2% over the past year and currently trades at $0.65.
According to Nasdaq Marketplace Rule 5550(a)(2), the bid price of a listed company’s stock must not fall below $1.00 per share. MetaVia Inc.’s stock failed to meet this criterion, prompting the notice from Nasdaq’s Listing Qualifications Department. InvestingPro analysis reveals the company’s weak financial health score of 1.32, with concerning metrics including rapid cash burn and poor profit margins. Subscribers can access 15 additional key insights about MetaVia’s financial condition.
MetaVia Inc. has been given a 180-day period, until November 25, 2025, to regain compliance. To achieve this, the closing bid price of the company’s common stock must reach or exceed $1.00 per share for at least 10 consecutive business days during this period. If MetaVia Inc. meets this requirement, Nasdaq will provide written confirmation that the company has regained compliance.
If the company fails to comply by the specified date, it may be eligible for an additional 180-day period, provided it meets all other initial listing standards for The Nasdaq Capital Market, except for the bid price requirement. The company would need to notify Nasdaq of its intent to remedy the deficiency, potentially through a reverse stock split.
In the event that MetaVia Inc. does not regain compliance within the allotted timeframe, including any extensions, Nasdaq will issue a delisting notice. The company would then have the right to appeal the decision to a Nasdaq hearings panel.
MetaVia Inc. has stated its intention to monitor its closing bid price closely and to explore all available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. The stock is currently trading near its 52-week low of $0.65, down significantly from its high of $5.30. However, there is no assurance that the company will be able to meet the Nasdaq listing requirements within the compliance period or after any extensions. InvestingPro subscribers can access detailed financial analysis, including Fair Value estimates and comprehensive company health metrics to better assess the stock’s potential.
This news is based on a press release statement from MetaVia Inc. and reflects the company’s current situation regarding its Nasdaq listing status.
In other recent news, MetaVia Inc. has secured approximately $10 million through a private placement to fund the clinical development of its obesity treatment, DA-1726. This financial move includes the sale of roughly 9.5 million shares of common stock and over 4.6 million pre-funded warrants, with Ladenburg Thalmann & Co. Inc. acting as the exclusive agent for the offering. Additionally, MetaVia has reported promising results from its Phase 1 clinical trial of DA-1726, which showed a significant reduction in body mass index (BMI) and weight among participants. The study highlighted the drug’s safety and tolerability, with no significant cardiovascular effects observed. Furthermore, MetaVia’s DA-1241, another drug candidate, demonstrated positive outcomes in a Phase 2a trial for Metabolic Dysfunction-Associated Steatohepatitis (MASH), indicating potential hepatoprotective and glucose-regulating effects. The results of this trial will be presented at the European Association for the Study of the Liver Congress. These developments underscore MetaVia’s ongoing efforts in advancing treatments for cardiometabolic diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.